Interestingly, deletion of CDKN2A has been reported as concurrent resistance mechanism in two NSCLC patients treated with Abivertinib, a third generation tyrosine kinase/EGFR inhibitor (32). This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.